BIOGRAPHICAL SKETCH (PI) Name: Hideshi Okada Degree(s): M.D., Ph.D. Position/Title: Postdoctoral Fellow Education/Training: (Begin with entry into college and include postdoctoral training)
Medicine, Gifu, Japan Hyogo Prefectural Amagasaki
Hospital, Hyogo, Japan Hyogo Prefectural Amagasaki
Hospital, Hyogo, Japan Gifu University Hospital, Gifu
Institute, La Jolla, CA, USA Veterans Medical Research Foundation, San Diego, CA,
1) Positions / employment
Assistant Professor - Advanced Critical Care Center, Gifu University Hospital, Gifu, Japan, Professor. Shin-ji Ogura
Research Associate – Immunology – The Scripps Research Institute, La Jolla, CA Professor. Jiahuai Han
Postdoctoral Fellow – Cardiology – Veterans Medical Research Foundation, San Diego, CA, Professor. Robert Scott Ross
Memberships / Honors
1) American Heart Association 2) Japanese Circulation Society 3) The Japanese Heart Failure Society 4) The Japanese Society of Internal Medicine 5) Japanese Society of Interventional Cardiology 6) The Japanese Society for Oriental Medicine 7) The Japan Society of Acupuncture and Moxibustion
BIOGRAPHICAL SKETCH (PI) continued 2) Peer Reviewed Publications (in English)
Li L, Okada H (equally contribute), Takemura G, Esaki M, Kobayashi H, Kanamori H, Kawamura I, Maruyama R, Fujiwara T, Fujiwara H, Tabata Y, Minatoguchi S. Sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres persistently improves lower leg ischemia. J Am Coll Cardiol. 2009 Jun 23;53(25):2378-88. Okada H, Takemura G, Kosai K, Tsujimoto A, Esaki M, Takahashi T, Nagano S, Kanamori H, Miyata S, Li Y, Ohno T, Maruyama R, Ogino A, Li L, Nakagawa M, Nagashima K, Fujiwara T, Fujiwara H, Minatoguchi S. Combined therapy with cardioprotective cytokine administration and anti-apoptotic gene transfer in postinfarction heart failure. Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H616-26.
Nakagawa M, Takemura G, Kanamori H, Goto K, Maruyama R, Tsujimoto A, Ohno T, Okada H, Ogino A, Esaki M, Miyata S, Li L, Ushikoshi H, Aoyama T, Kawasaki M, Nagashima K, Fujiwara T, Minatoguchi S, Fujiwara H. Mechanisms by which late coronary reperfusion mitigates postinfarction cardiac remodeling. Circ Res. 103(1):98-106. 2008 Okada H, Takemura G, Li Y, Ohno T, Li L, Maruyama R, Esaki M, Miyata S, Kanamori H, Ogino A, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Effect of a long-term treatment with a low-dose granulocyte colony-stimulating factor on post-infarction process in the heart. J Cell Mol Med. 12(4):1272-83. 2008
Esaki M, Takemura G, Kosai K, Takahashi T, Miyata S, Li L, Goto K, Maruyama R, Okada H, Kanamori H, Ogino A, Ushikoshi H, Minatoguchi S, Fujiwara T, Fujiwara H.Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 294(2):H1048-57. 2008
Ogino A, Takemura G, Kanamori H, Okada H, Maruyama R, Miyata S, Esaki M, Nakagawa M, Aoyama T, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara T, Fujiwara H. Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. Am J Physiol Heart Circ Physiol. 293(4): H2271-80. 2007
Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail. 13(2):155-62. 2007
Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest. 87(5):440-55. 2007
Kanamori H, Takemura G, Li Y, Okada H, Maruyama R, Aoyama T, Miyata S, Esaki M, Ogino A, Nakagawa M, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara H. Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Am J Physiol Heart Circ Physiol. 292(5):H2184-94. 2007
Li Y, Takemura G, Okada H, Miyata S, Kanamori H, Maruyama R, Esaki M, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. G II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart. Am J Physiol Heart Circ Physiol. 292(2):H946-53. 2007
Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H. Autophagic degeneration and death of cardiomyocytes in heart failure. Autophagy. 2(3) 212-4. 2006
Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 71(4) 684-94. 2006
Koda M, Takemura G, Okada H, Kanoh M, Maruyama R, Esaki M, Li Y, Miyata S, Kanamori H, Li L, Ogino A, Kondo T, Minatoguchi S, Fujiwara T, Fujiwara H. Nuclear hypertrophy reflects increased biosynthetic activities in myocytes of human hypertrophic hearts. Circ J. 2006 Jun;70(6):710-8.
Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kanamori H, Li L, Misao Y, Tezuka A, Toyo-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H. Autophagic Cardiomyocyte death in Cardiomyopathic Hamsters and Its Prevention by Granulocyte Colony-stimulating Factor. Am J Pathol. 168(2) 386-97. 2006
Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, Minatoguchi S, Fujiwara T, Fujiwara H. Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-induced Cardiomyopathy. Circulation. 113(4) 535-43. 2006
Li Y, Takemura G, Okada H, Miyata S, Esaki M, Maruyama R, Kanamori H, Li L, Ogino A, Misao Y, Khai NC, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Treatment with Granulocyte Colony-stimulating Factor Ameliorates Chronic Heart Failure. Lab Invest. 86(1) 32-44. 2006 Okada H, Takemura G, Koda M, Kanoh M, Kawase Y, Minatoguchi S, Fujiwara H .Myocardial Apoptotic Index Based on In Situ DNA Nick End-labeling of Endomyocardial Biopsies Dose Not Predict Prognosis of Dilated Cardiomyopathy. Chest 2005 128(2):1060-2 Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Postinfarction Gene Therapy Against Transforming Growth Factor-β Signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure. Circulation 2005;111(19):2430-7.
Saijo M, Takemura G, Koda M, Okada H, Miyata S, Ohno Y, Kawasaki M, Tsuchiya K, Nishigaki K, Minatoguchi S, Goto K, Fujiwara H: Cardiomyopathy with prominent autophagic degeneration, accompanied by an elevated plasma brain natriuretic level despite the lack of overt heart failure. Intern Med. 2004;43(8):700-3.
Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Miyata S, Yuge K, Nagano S, Esaki M, Khai NC, Goto K, Mikami A, Maruyama R, Minatoguchi S, Fujiwara T, Fujiwara H: Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ Res. 2004;95(6):627-36.
Hayakawa K, Takemura G, Kanoh M, Li Y, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Fujiwara T, Fujiwara H: Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunction at the chronic stage. Circulation. 2003;108(1):104-9.
Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T, Matsumori A, Takatsu Y: Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart. 2003;89(6):659-60.
Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Mizuguchi H, Fujiwara T, Fujiwara H: Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation. 2003;107(19):2499-506.
Sato Y, Taniguchi R, Makiyama T, Nagai K, Okada H, Yamada T, Matsumori A, Takatsu Y: Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart. 2002;88(6):647-8.
Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y: Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103(3):369-74.
Nakamura Y, Okada H, Wada Y, Kajiyama K, Koshiyama H: Lymphocytic hypophysitis: its expanding features. J Endocrinol Invest. 2001;24(4):262-7.
Sato Y, Taniguchi R, Yamada T, Nagai K, Makiyama T, Okada H, Matsumori A, Sasayama S, Takatsu Y: Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med. 2000;39(4):350. Abstracts
1. Okada H, Takemura G, Kosai K, Li Y, Esaki M, Takahashi T, Kanamori H, Ogino A,
Miyata S, Minatoguchi S, Fujiwara T, Fujiwara H. Combination Therapy with Granulocyte- Colony Stimulating Factor and Antiapoptotic Soluble Fas Gene Delivery in Postinfarction Heart Failure. AHA 79, Chicago, USA, 2006
2. Okada H, Takemura G, Li Y, Maruyama R, Kanamori H, Li L, Misao Y, Minatoguchi S,
Fujiwara T, Fujiwara H. G-CSF Displays Its Beneficial Effects on Postinfarction Cardiac Function by Cardiomyocyte Hypertrophy and Anti-fibrosis, But Not by Angiogenesis, Regeneration, or Anti-apoptosis of Cardiomyocytes. AHA 78, Dallas, USA, 2005
3. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S,
Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Postinfarction Gene Therapy Against Transforming Growth Factor-β Signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure. AHA 77, New Orleans, USA, 2004
3) Research Support (last three years)
Award with Grant for outstanding young researchers Funding agency:
Cytokine Therapy in Postinfarct Heart Failure
The overall goals of the project: G-CSF displays its beneficial effects on postinfarction cardiac function by cardiomyocyte hypertrophy and anti-fibrosis, but not by angiogenesis, regeneration, or anti-apoptosis of cardiomyocytes.
Award for outstanding young researchers Funding Agency:
Gifu University School of Medicine alumni society
Postinfarction Gene Therapy Against TGF-β Signal
The overall goals of the project: Postinfarction gene therapy against Transforming Growth Factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
Principal investigator: Award with Grant for outstanding young researchers Funding Agency:
Decorin Gene Delivery in Postinfarct Heart Failure
The overall goals of the project: Decorin gene delivery inhibit cardiac fibrosis of infarct tissue and attenuates left ventricular remodeling and heart failure.
Lilly International fellowship: Grant from the Eli Lilly foundation Funding Agency:
Analysis of TNF-α expression from macrophage
Date of Award : Jun. 2006 The overall goals of the project: We use retrovirus insertion-mediated random mutagenesis and identify the candidate molecule which is necessary for TNF-α production by LPS stimulation from macrophage.
The Uehara Memorial Foundation: Grant from The Uehara Memorial Foundation Funding Agency:
Analysis of TNF-α expression from macrophage
Date of Award : Dec. 2007 The overall goals of the project: We use retrovirus insertion-mediated random mutagenesis and identify the candidate molecule which is necessary for TNF-α production by LPS stimulation from macrophage.
Hemolymphatic/Oncology Blood Parasites in the Dog and Cat: Haemobartonellosis: Haemobartonella sp. are gram negative, non-acid fast, epicellular parasites of erythrocytes. Haemobartonella canis and Haemobartonella felis are the species that affect dogs and cats, respectively. Experimentally, cats have been reported to have a subclinical infection with H. canis . Haemobartonella organi
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel- group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients Why is this research study being done? We are studying an “investigational” drug, lorcaserin hydrochloride (“lorcaserin�